Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Australian biotech giant CSL is teaming up with Amazon Web Services to bring AI and cloud technology into its drug research and clinical development pipeline. The partnership aims to speed up drug discovery, cut manual workloads in clinical processes, and tighten the link between lab work and computational research — a big bet on tech to shorten the long road from lab bench to patient.
Australian biotech giant CSL is going all-in on AI and cloud computing, announcing a new collaboration with Amazon Web Services (AWS) to transform how it discovers and develops drugs. The partnership will give CSL's scientists powerful tools to analyse complex scientific data and pinpoint potential drug targets earlier in the discovery process — a move designed to shave time off notoriously long development timelines.
On the clinical side, CSL plans to use AWS's AI tools to reduce the manual grind of protocol drafting, data management, and regulatory submissions. The company also wants to more tightly integrate its lab and computational work, so that experimental results can feed back into research models faster and more efficiently.
Key Takeaways:
Why it matters: As drug development costs and timelines continue to grow, AI-powered partnerships like this one signal a broader industry shift toward tech-driven R&D. For healthcare professionals and patients alike, faster and smarter drug discovery could mean new therapies reaching the clinic sooner.